169 related articles for article (PubMed ID: 6870293)
21. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
22. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
25. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors.
Wallqvist A; Huang R; Covell DG
J Chem Inf Model; 2007; 47(4):1414-27. PubMed ID: 17555311
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.
Wosikowski K; Biedermann E; Rattel B; Breiter N; Jank P; Löser R; Jansen G; Peters GJ
Clin Cancer Res; 2003 May; 9(5):1917-26. PubMed ID: 12738750
[TBL] [Abstract][Full Text] [Related]
27. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
28. Modes of resistance to antitumor agents.
Kessel D
In Vivo; 1994; 8(5):829-34. PubMed ID: 7727732
[TBL] [Abstract][Full Text] [Related]
29. [A glycolytic marker test for individualizing the selection of chemical compounds for antitumor activity].
Piruzian LA; Mikhaĭlovskiĭ EM
Izv Akad Nauk SSSR Biol; 1992; (1):111-22. PubMed ID: 1583204
[TBL] [Abstract][Full Text] [Related]
30. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
31. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.
Staquet MJ; Byar DP; Green SB; Rozencweig M
Cancer Treat Rep; 1983 Sep; 67(9):753-65. PubMed ID: 6883351
[TBL] [Abstract][Full Text] [Related]
32. A model-based approach to the in vitro evaluation of anticancer activity.
Del Bene F; Germani M; De Nicolao G; Magni P; Re CE; Ballinari D; Rocchetti M
Cancer Chemother Pharmacol; 2009 Apr; 63(5):827-36. PubMed ID: 18663447
[TBL] [Abstract][Full Text] [Related]
33. [Current results and perspectives of the use of human tumor cell lines for antitumor drug screening].
Zhukova OS; Dobrynin IaV
Vopr Onkol; 2001; 47(6):706-9. PubMed ID: 11826493
[TBL] [Abstract][Full Text] [Related]
34. New preclinical models for testing antitumor drugs. The immuno-chemotherapy index.
Frati L; Riccardi C; Bartocci A; Bonmassar E
Arch Geschwulstforsch; 1978; 48(7):660-4. PubMed ID: 736747
[No Abstract] [Full Text] [Related]
35. Evaluation of Madison 109 lung carcinoma as a model for screening antitumor drugs.
Rose WC
Cancer Treat Rep; 1981; 65(3-4):299-312. PubMed ID: 7237452
[TBL] [Abstract][Full Text] [Related]
36. Screening for and identification of novel agents directed at renal cell carcinoma.
Mertins SD; Myers TG; Hollingshead M; Dykes D; Bodde E; Tsai P; Jefferis CA; Gupta R; Linehan WM; Alley M; Bates SE
Clin Cancer Res; 2001 Mar; 7(3):620-33. PubMed ID: 11297258
[TBL] [Abstract][Full Text] [Related]
37. The influence of three newly synthesized pyrimidine-containing compounds on micronucleus induction and tumor growth.
Nersesyan A; Muradyan R; Arsenyan F
J BUON; 2007; 12(4):521-7. PubMed ID: 18067211
[TBL] [Abstract][Full Text] [Related]
38. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
Kim K; Blechman WJ; Riddle VG; Pardee AB
Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang S; Houghton PJ
Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
[TBL] [Abstract][Full Text] [Related]
40. Update on NCI in vitro drug screen utilities.
Holbeck SL
Eur J Cancer; 2004 Apr; 40(6):785-93. PubMed ID: 15120034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
